Trial intelligence / Profile preview

COMPARE-VS: Vicadrostat vs Spironolactone in CKD with CVD/HF

NCT07304817Phase 2

Key facts

Status: Recruiting
Start: May 2026
Primary completion: Feb 2028
Countries: 1
Sponsor: University Medical Center Groningen
Modality: Small Molecules

Drugs: vicadrostat
Conditions: chronic kidney disease (CKD)cardiovascular disease (CVD)heart failure (HF)

Overview

Phase 2, randomised, open-label trial of vicadrostat in chronic kidney disease (CKD), cardiovascular disease (CVD) and heart failure (HF) (2 arms), sponsored by University Medical Center Groningen. Primary endpoint: Estimated Glomerular Filtration Rate at 26 weeks. Started May 2026; status: recruiting.

Design

2 arms

Study design: RandomizedOpen-label

Vicadrostat
Vicadrostat 10mg + Empagliflozin 10mg daily for 26 weeks
Spironolactone
Spironolactone 25mg + Empagliflozin 10mg daily for 4 weeks, then Spironolactone 50mg + Empagliflozin 10mg daily for 22 weeks

Who it enrols

Adult outpatients with chronic kidney disease and either heart failure or cardiovascular disease, with eGFR between 25-90 mL/min/1.73m2, serum potassium <= 5.0 mmol/L, and currently treated or eligible for empagliflozin.

Endpoints

Primary

Estimated Glomerular Filtration Rate26 weeks

Secondary

Renal hemodynamic measurements26 weeks
Plasma protein profiles26 weeks
Urinary protein profiles26 weeks
Blood concentration markers26 weeks
Urinary concentration markers26 weeks
Urine Albumin-to-Creatinine Ratio26 weeks

Beyond the preview

Go deeper on NCT07304817.

Full results, competitive context and analysis are in the Gosset platform.

Full results & analysis

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT07304817.